A Physician-Focused Intervention to Reduce Potentially Inappropriate Medication Prescribing in Older People
Potentially inappropriate medications (PIMs) are a preventable cause of negative clinical and economic consequences in older people. A range of educational interventions have attempted to address this in the past and have produced mixed results.
The objective of this study was to assess the effect of a physician-focused, multi-factorial, quality-improvement intervention on PIM prescribing in older patients in primary care.
This 3-year, multi-phase, prospective, proof-of-concept project introduced in 2007 was aimed at engaging all 303 general practitioners (GPs) in the Local Health Authority (LHA) of Parma, Italy, to positively influence the quality of prescribing to the entire older outpatient population (those aged at least 65 years) served by these physicians. The intervention focused on increasing GPs’ awareness of prescribing for older people and included three key elements: (1) initial dissemination of a developed list of PIMs to always be avoided, along with a list of alternative drugs; (2) annual reviews of PIM incidence data; and (3) educational sessions on PIMs via academic detailing and case study reviews. Quarterly incidence rates of PIM exposure were calculated among all Parma LHA older outpatients who had received a prescription for any medication from their GP in a given quarter. The intervention was assessed by evaluating the changes in these rates between the study baseline (2007 fourth quarter [Q4]) and the end of the study (post-intervention: 2009 Q4). To reduce bias and confounding from background influences that may have acted to reduce PIM incidence rates independent of the intervention, these rate changes were also compared with those drawn from a similar neighbouring LHA over the same time period.
Quarterly PIM exposure incidence rates among the older Parma LHA patients declined 31.4 % (7.8 % baseline to 5.3 % post-intervention), compared with 21.6 % in the comparator LHA (7.7 % to 6.1 %). The reduction in rates was significantly greater in the Parma LHA (p < 0.001), where the intervention resulted in 608 older patients (12.4 % of expected) being spared PIM exposure during 2009 Q4. PIM exposure rate reductions for NSAIDs and digoxin were each significantly greater in the Parma LHA than in the comparator LHA.
By reaching out to GPs and maintaining contact with them, this quality intervention appears to have positively impacted physicians’ awareness and prescribing behaviour, which led to significant reductions in PIM exposures and likely translated to significant population health benefits among their older patients. Similar interventions tailored to target specific PIMs or focus on certain subpopulations of GPs may further improve prescribing quality among older people.
- 6.Fick DM, Waller JL, Maclean JR, et al. Potentially inappropriate medication use in a Medicare managed care population: association with higher costs and utilization. JMCP. 2001;7(5):407–13.Google Scholar
- 14.Agenzia Italiana del Farmaco. Piroxicam: ulteriori restrizioni e avvertenze sulla sicurezza. Farmacovigilanza. 2007 Dec 20; Bif XIV No. 6: 261–262. http://www.agenziafarmaco.gov.it/sites/default/files/bif6_piroxicam.pdf. Accessed 2012 Mar 10.
- 18.European Medicines Agency Press Office. Key elements for the summaries of product characteristics of non-selective NSAIDs adopted by the CHMP during its meeting in October 2005 (EMEA/CHMP/343456/2005). London: EMEA; 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/02/WC500074137.pdf. 2012 Mar 21.
- 20.Louis DZ, Yuen EJ, Maio V, et al. A population-based longitudinal healthcare database in the Emilia-Romagna Region, Italy: a resource for planning and research. Health Policy Newsletter. 2005;18(2):6.Google Scholar
- 21.Institute of Internal Medicine (IOM). To err is human: building a safer health system. Washington, D.C: National Academy Press; 2001.Google Scholar
- 24.United States Food and Drug Administration. Pergolizzi VM. Addressing NSAID safe use: primum non nocere. Silver Spring: FDA; 2009. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM234184.pdf. Accessed 2012 Mar 21.